407 related articles for article (PubMed ID: 22224673)
1. New and emerging disease modifying therapies for multiple sclerosis.
Saidha S; Eckstein C; Calabresi PA
Ann N Y Acad Sci; 2012 Jan; 1247():117-37. PubMed ID: 22224673
[TBL] [Abstract][Full Text] [Related]
2. Emerging oral agents for multiple sclerosis.
Fox EJ
Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
[TBL] [Abstract][Full Text] [Related]
3. Emerging oral drugs for relapsing-remitting multiple sclerosis.
Gasperini C; Ruggieri S
Expert Opin Emerg Drugs; 2011 Dec; 16(4):697-712. PubMed ID: 22148963
[TBL] [Abstract][Full Text] [Related]
4. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
5. Dimethyl fumarate for multiple sclerosis.
Papadopoulou A; D'Souza M; Kappos L; Yaldizli O
Expert Opin Investig Drugs; 2010 Dec; 19(12):1603-12. PubMed ID: 21067468
[TBL] [Abstract][Full Text] [Related]
6. Emerging disease-modifying oral therapies for multiple sclerosis.
Losy J; Kalinowska-Łyszczarz A
J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
[TBL] [Abstract][Full Text] [Related]
7. Currently approved and emerging oral therapies in multiple sclerosis: An update for the ophthalmologist.
Eckstein C; Bhatti MT
Surv Ophthalmol; 2016; 61(3):318-32. PubMed ID: 26703886
[TBL] [Abstract][Full Text] [Related]
8. Current and future disease-modifying therapies in multiple sclerosis.
Lim SY; Constantinescu CS
Int J Clin Pract; 2010 Apr; 64(5):637-50. PubMed ID: 20456216
[TBL] [Abstract][Full Text] [Related]
9. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
10. Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Hohlfeld R; Barkhof F; Polman C
Neurology; 2011 Feb; 76(8 Suppl 3):S28-37. PubMed ID: 21339488
[TBL] [Abstract][Full Text] [Related]
11. Promising emerging therapies for multiple sclerosis.
Giovannoni G
Neurol Clin; 2011 May; 29(2):435-48. PubMed ID: 21439452
[TBL] [Abstract][Full Text] [Related]
12. Therapy of MS.
Vosoughi R; Freedman MS
Clin Neurol Neurosurg; 2010 Jun; 112(5):365-85. PubMed ID: 20362388
[TBL] [Abstract][Full Text] [Related]
13. Cladribine as a therapeutic option in multiple sclerosis.
Warnke C; Leussink VI; Goebels N; Aktas O; Boyko A; Kieseier BC; Hartung HP
Clin Immunol; 2012 Jan; 142(1):68-75. PubMed ID: 21733757
[TBL] [Abstract][Full Text] [Related]
14. Emerging therapies in multiple sclerosis.
Farrell R; Heaney D; Giovannoni G
Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
[TBL] [Abstract][Full Text] [Related]
15. [Multiple sclerosis: current therapies and future perspectives].
Matsushita T
Nihon Rinsho; 2011 Nov; 69(11):2077-86. PubMed ID: 22111333
[TBL] [Abstract][Full Text] [Related]
16. Principles of a new treatment algorithm in multiple sclerosis.
Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T
Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441
[TBL] [Abstract][Full Text] [Related]
17. Emerging oral therapies for multiple sclerosis.
Cohen BA; Rieckmann P
Int J Clin Pract; 2007 Nov; 61(11):1922-30. PubMed ID: 17784852
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for multiple sclerosis: current and emerging therapies.
Gawronski KM; Rainka MM; Patel MJ; Gengo FM
Pharmacotherapy; 2010 Sep; 30(9):916-27. PubMed ID: 20795847
[TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.
Wingerchuk DM
Expert Rev Neurother; 2006 Mar; 6(3):333-46. PubMed ID: 16533138
[TBL] [Abstract][Full Text] [Related]
20. [New and emerging treatments for multiple sclerosis].
Louapre C; Maillart É; Papeix C; Lubetzki C
Med Sci (Paris); 2013 Dec; 29(12):1105-10. PubMed ID: 24356140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
